• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一项前瞻性研究显示,大样本地中海贫血中间型成年患者中外髓造血与转铁蛋白受体可溶性形式水平之间存在有益关系。

A useful relationship between the presence of extramedullary erythropoeisis and the level of the soluble form of the transferrin receptor in a large cohort of adult patients with thalassemia intermedia: a prospective study.

机构信息

UOSD Centro delle Microcitemie "A. Mastrobuoni", AORN A. Cardarelli, Naples, Italy.

出版信息

Ann Hematol. 2012 Jun;91(6):905-9. doi: 10.1007/s00277-011-1385-y. Epub 2011 Dec 15.

DOI:10.1007/s00277-011-1385-y
PMID:22167341
Abstract

In thalassemia intermedia (TI), the increase in bone marrow hemopoietic activity frequently leads to extramedullary erythropoeisis (EMH), but its relationship with the soluble form of transferrin receptor (sTfR) which fully reflects the marrow erythropoietic activity, has not yet been explored. From January 2007 to December 2010, all TI patients attending at our center were prospectively enrolled to undergo sTfR assay and MRI or CT (if claustrophobic) scan evaluation for the presence of paraspinal EMH. A total of 59 patients with TI were studied; EMH involved 23 (39%) patients; overall, the concentration of sTfR varied from 2.6 to 20.6 (mean = 8.7) mg/L, but in splenectomized group and in unsplenectomized group, it varied from 4.2 to 17.8 (mean ± SD = 9.86 ± 3.33) mg/L and from 2.6 to 20.6 (mean ± SD = 7.25 ± 3.9) mg/L, respectively with a statistically significant intergroup difference (p < 0.01). The cutoff point at 8.6 mg/L using the ROC curve showed a sensitivity of 78.3% and a specificity of 72.2%, in predicting EMH but, in unsplenectomized subgroup, they raised to 100% and 90.9%, respectively. These data showed that in TI the level of sTfR could represent a predictive factor of EMH particularly in patients with spleen.

摘要

在地中海贫血中间型(TI)中,骨髓造血活性的增加常导致骨髓外红细胞生成(EMH),但其与完全反映骨髓红细胞生成活性的可溶性转铁蛋白受体(sTfR)的关系尚未得到探索。 2007 年 1 月至 2010 年 12 月,我们中心所有的 TI 患者均前瞻性入组,接受 sTfR 检测和 MRI 或 CT(如果幽闭恐惧症)扫描评估脊柱旁 EMH 的存在。共有 59 例 TI 患者进行了研究; EMH 涉及 23 例(39%)患者;总体而言,sTfR 的浓度范围为 2.6 至 20.6(平均值为 8.7)mg/L,但在脾切除组和未脾切除组中,浓度范围分别为 4.2 至 17.8(平均值±SD=9.86±3.33)mg/L 和 2.6 至 20.6(平均值±SD=7.25±3.9)mg/L,两组之间存在统计学差异(p <0.01)。使用 ROC 曲线确定的 8.6mg/L 截断值显示出预测 EMH 的敏感性为 78.3%,特异性为 72.2%,但在未脾切除亚组中,敏感性和特异性分别提高到 100%和 90.9%。这些数据表明,在 TI 中,sTfR 水平可以作为 EMH 的预测因子,特别是在有脾脏的患者中。

相似文献

1
A useful relationship between the presence of extramedullary erythropoeisis and the level of the soluble form of the transferrin receptor in a large cohort of adult patients with thalassemia intermedia: a prospective study.一项前瞻性研究显示,大样本地中海贫血中间型成年患者中外髓造血与转铁蛋白受体可溶性形式水平之间存在有益关系。
Ann Hematol. 2012 Jun;91(6):905-9. doi: 10.1007/s00277-011-1385-y. Epub 2011 Dec 15.
2
Erythroid bone marrow activity and red cell hemoglobinization in iron sufficient beta-thalassemia heterozygotes as reflected by soluble transferrin receptor and reticulocyte hemoglobin in content. Correlation with genotypes and Hb A(2) levels.可溶性转铁蛋白受体和网织红细胞血红蛋白含量所反映的铁充足的β地中海贫血杂合子的红系骨髓活性和红细胞血红蛋白化。与基因型和Hb A(2)水平的相关性。
Haematologica. 2003 Jun;88(6):631-6.
3
Serum erythropoietin and circulating transferrin receptor in thalassemia intermedia patients with heterogeneous genotypes.中间型地中海贫血不同基因型患者的血清促红细胞生成素和循环转铁蛋白受体
Haematologica. 1996 Sep-Oct;81(5):397-403.
4
Erythropoiesis and Iron Homeostasis in Non-Transfusion-Dependent Thalassemia Patients with Extramedullary Hematopoiesis.非输血依赖型地中海贫血伴髓外造血患者的红细胞生成和铁稳态。
Biomed Res Int. 2019 Jan 30;2019:4504302. doi: 10.1155/2019/4504302. eCollection 2019.
5
Serum transferrin receptor levels in beta-thalassemia trait.β地中海贫血特征患者的血清转铁蛋白受体水平
J Trop Pediatr. 2004 Dec;50(6):369-71. doi: 10.1093/tropej/50.6.369.
6
Serum levels of erythropoietin and soluble transferrin receptor in the course of pregnancy in non beta thalassemic and beta thalassemic women.非β地中海贫血和β地中海贫血女性孕期血清促红细胞生成素和可溶性转铁蛋白受体水平
Haematologica. 2000 Sep;85(9):902-7.
7
Innovative parameters RET-Y, sTfR, and sTfR-F index in patients with microcytic, hypochromic anemia--their special value for hemoglobinopathies.小细胞低色素性贫血患者的创新参数RET-Y、可溶性转铁蛋白受体(sTfR)和sTfR-F指数——它们对血红蛋白病的特殊价值。
Lab Hematol. 2007;13(2):63-8. doi: 10.1532/LH96.06044.
8
Lipid profile in beta-thalassemia intermedia patients: correlation with erythroid bone marrow activity.中间型β地中海贫血患者的血脂谱:与红系骨髓活性的相关性
Int J Lab Hematol. 2007 Jun;29(3):172-6. doi: 10.1111/j.1751-553X.2006.00862.x.
9
Clinical utility of serum soluble transferrin receptor levels and comparison with bone marrow iron stores as an index for iron-deficient erythropoiesis in a heterogeneous group of patients.血清可溶性转铁蛋白受体水平的临床应用及与骨髓铁储存的比较作为异质性患者群体缺铁性红细胞生成指标的研究
Pathology. 2007 Jun;39(3):349-53. doi: 10.1080/00313020701329732.
10
Sensitivity, specificity, and predictive value of serum soluble transferrin receptor at different stages of iron deficiency.血清可溶性转铁蛋白受体在缺铁不同阶段的敏感性、特异性及预测价值。
Ann Clin Lab Sci. 2005 Autumn;35(4):435-9.

引用本文的文献

1
Haematological parameters in erythropoietic protoporphyria: A multi-national study.红细胞生成性原卟啉病的血液学参数:一项多国研究。
Br J Haematol. 2025 Jun 10. doi: 10.1111/bjh.20197.
2
Effective non-surgical management of spinal cord compression from extra-medullary hematopoiesis with radiotherapy in thalassemia intermedia: a case report.中间型地中海贫血髓外造血致脊髓压迫症的有效非手术放疗管理:一例报告
Oxf Med Case Reports. 2025 May 28;2025(5):omaf039. doi: 10.1093/omcr/omaf039. eCollection 2025 May.
3
Impact of genotype on multi-organ iron and complications in patients with non-transfusion-dependent β-thalassemia intermedia.
基因型对非输血依赖型β-中间型地中海贫血患者多器官铁沉积及并发症的影响。
Ann Hematol. 2024 Jun;103(6):1887-1896. doi: 10.1007/s00277-024-05741-9. Epub 2024 Apr 6.
4
Iron-related Biomarkers in the Diagnosis and Management of Iron Disorders.铁相关生物标志物在铁代谢紊乱诊断和管理中的应用。
Curr Med Chem. 2024;31(27):4233-4248. doi: 10.2174/0109298673263003231228060800.
5
Long-term safety and erythroid response with luspatercept treatment in patients with β-thalassemia.卢司帕安治疗β地中海贫血患者的长期安全性和红系反应
Ther Adv Hematol. 2022 Dec 5;13:20406207221134404. doi: 10.1177/20406207221134404. eCollection 2022.
6
The Correlation Between Ineffective Erythropoiesis Biomarkers and Development of Extramedullary Hematopoiesis in Patients with Thalassemia.地中海贫血患者无效红细胞生成生物标志物与髓外造血发展的相关性
Mediterr J Hematol Infect Dis. 2022 Jul 1;14(1):e2022052. doi: 10.4084/MJHID.2022.052. eCollection 2022.
7
Thalassemia and hepatocellular carcinoma: links and risks.地中海贫血与肝细胞癌:关联与风险
J Blood Med. 2019 Sep 17;10:323-334. doi: 10.2147/JBM.S186362. eCollection 2019.
8
Erythropoiesis and Iron Homeostasis in Non-Transfusion-Dependent Thalassemia Patients with Extramedullary Hematopoiesis.非输血依赖型地中海贫血伴髓外造血患者的红细胞生成和铁稳态。
Biomed Res Int. 2019 Jan 30;2019:4504302. doi: 10.1155/2019/4504302. eCollection 2019.
9
Imbalance of erythropoiesis and iron metabolism in patients with thalassemia.地中海贫血患者的红细胞生成和铁代谢失衡。
Int J Med Sci. 2019 Jan 1;16(2):302-310. doi: 10.7150/ijms.27829. eCollection 2019.
10
Iron overload across the spectrum of non-transfusion-dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions.非输血依赖型地中海贫血症中的铁过载:红细胞生成、脾切除术及输血的作用
Br J Haematol. 2017 Jan;176(2):288-299. doi: 10.1111/bjh.14373. Epub 2016 Dec 5.